Cyclosporine Intracanalicular Insert Successful Through 16 Weeks

In Western Colorado Eyecare Professional using high tech equipment in eyecare clinic setting part of series with millennial male and female patient (Shot with Canon 5DS 50.6mp photos professionally retouched – Lightroom / Photoshop – original size 5792 x 8688 downsampled as needed for clarity and select focus used for dramatic effect)
Researchers saw improvements in signs and symptoms starting in week 2, and continuing through week 16.

This article is part of Ophthalmology Advisor’s Dry Eye Disease In-Depth coverage from the 2021 meeting of the American Academy of Ophthalmology, held in New Orleans from November 12 to 15, 2021. The team at Ophthalmology Advisor will be reporting on a variety of the research presented by the dry eye disease experts at the AAO. Check back for more from the AAO 2021 Meeting.


Patients with dry eye disease who were treated with cyclosporine intracanalicular insert (OTX-CSI) saw improvements in their ocular surface health, according to research presented at the American Academy of Ophthalmology 2021 meeting, held in New Orleans, November 12-15. 

Patients with DED were recruited to this ongoing phase 1/2 trial and received either 0.36 mg OTX-CSI or vehicle. The trial was composed of 2 cohorts. Cohort 1 was run open-label (n=5), and cohort 2 (n=140) was conducted as a randomized, double-masked, vehicle-controlled study examining 2 formulations of OTX-CSI and vehicle. Over 16 weeks data were collected using Schirmer test (unanesthetized) corneal fluorescein staining (CFS; NEI scale), eye dryness score visual analogue scale (VAS; 0-100 scale) and adverse events (AE). 

In Cohort 1, no adverse events were reported and there was an improvement in the mean Schirmer test scores from baseline to week 16 (4.2 to 8.5 mm). One subject in this cohort achieved a greater than 10 mm increase (7 to 17 mm) by week 12. Week 12 also showed the greatest reduction in CFS from baseline (6.7 to 2.7). Additionally, average visual analogue scales, dryness severity, and frequency scores improved from baseline to week 16 (51 to 23 and 51 to 28, respectively). 

The presenters explained that the follow-up for cohort 2 is ongoing.

“Interim results showed OTX-CSI was generally safe and well tolerated, with no AEs observed,” according to the report. “Improvements in DED signs and symptoms started week 2 and were maintained to week 16.”

Visit Ophthalmology Advisor’s conference section for the complete Dry Eye Disease coverage from the AAO 2021.



Christie WC, Segal BA, Shettle L, McClain N, Blender N, Goldstein MH. Phase 1/2 trial evaluating a novel, hydrogel-based cyclosporine intracanalicular insert in subjects with DED. Poster presented at: The American Academy of Ophthalmology 2021Annual Meeting; November 12-15, 2021; New Orleans. Abstract PO170.